HeartBeam Inc. (NASDAQ: BEAT) announced on April 16, 2026, the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The offering, supported by key stakeholders including ClearCardio, company leadership, and institutional investors, is expected to fuel the commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities, and general corporate purposes.
The funding marks a critical milestone for HeartBeam as it seeks to bring its innovative cardiac monitoring technology to market. The company’s platform is designed to be the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This technology has received FDA clearance for arrhythmia assessment in December 2024 and for the 12-lead ECG synthesis software in December 2025, as noted in the company’s cleared indications for use.
HeartBeam’s approach addresses a significant gap in cardiac care by enabling portable, actionable heart intelligence outside of medical facilities. The company’s 3D ECG technology allows physicians to identify cardiac health trends and acute conditions, directing patients to appropriate care remotely. This could reduce the burden on emergency departments and improve outcomes for patients with heart conditions. With over 20 issued patents related to technology enablement, HeartBeam is positioning itself as a leader in the evolving field of remote cardiac monitoring.
The successful closing of this offering, detailed in the full press release available at IBN.fm, comes at a time when the demand for remote healthcare solutions continues to rise. The funds will be used to accelerate the commercialization of HeartBeam’s FDA-cleared system, which could potentially transform how cardiac conditions are detected and managed. The extended-wear patch and heart attack detection technologies under development could further expand the company’s product portfolio, offering continuous monitoring for patients at risk of acute cardiac events.
Investors and industry observers will be watching HeartBeam’s progress closely, as the company aims to redefine cardiac health management. The latest news and updates relating to BEAT are available in the company’s newsroom at IBN.fm/BEAT. With the fresh capital, HeartBeam is well-positioned to execute its strategy and potentially capture a significant share of the cardiac monitoring market.
